Table 1 Patients and clinical characteristics.

From: Omitting radiotherapy is safe in breast cancer patients ≥ 70 years old after breast-conserving surgery without axillary lymph node operation

 

Total

BCSNR

Mastectomy and axillary lymph node dissection

breast conserving surgery and axillary lymph node dissection

Mastectomy and sentinel lymph node biopsy

breast conserving surgery and sentinel lymph node biopsy

Age

N = 481

302

148

18

7

6

70–74

186 (38.7%)

94 (31.1%)

79 (53.4%)

6 (33.3%)

5 (71.4%)

2 (33.3%)

75–59

171 (35.6%)

106 (35.1%)

54 (36.5%)

8 (44.4%)

2 (28.6%)

1 (16.7%)

80+

124 (25.8%)

102(33.8%)

15 (10.1%)

4 (22.2%)

0 (0.0%)

3 (50.0%)

T stage

0

1 (0.2%)

0 (0.0%)

1 (0.7%)

0 (0.0%)

0 (0.0%)

0

1

284 (59.0%)

193 (63.9%)

73 (49.3%)

17 (94.4%)

1 (14.3%)

1 (16.7%)

2

182 (37.8%)

105 (34.8%)

66 (44.6%)

1 (5.6%)

6 (85.7%)

4 (66.7%)

3

13 (2.7%)

4 (1.3%)

8 (5.4%)

0 (0.0%)

0 (0.0%)

1 (16.7%)

4

1 (0.2%)

0 (0.0%)

1 (0.7%)

0 (0.0%)

0 (0.0%)

0

Histological grade

Un-known

71 (14.8%)

45 (14.9%)

19 (12.8%)

4 (22.2%)

2 (28.6%)

1 (16.7%)

1

105 (21.8%)

53 (17.5%)

46 (31.1%)

4 (22.2%)

1 (14.3%)

1 (16.7%)

2

231 (48.0%)

144 (47.7%)

72 (48.6%)

9 (50.0%)

2 (28.6%)

4 (66.7%)

3

74 (15.4%)

60 (19.9%)

11 (7.4%)

1 (5.6%)

2 (28.6%)

0 (0.0%)

HR

−

99 (20.6%)

52 (17.2%)

42 (28.4%)

3 (16.7%)

1 (14.3%)

1 (16.7%)

+

382(79.4%)

250 (82.8%)

106 (71.6%)

15 (83.3%)

6 (85.7%)

5 (83.3%)

Molecular type

Luminal A

176 (36.6%)

125 (41.4%)

36 (24.3%)

8 (44.4%)

6 (85.7%)

1 (16.7%)

Luminal B

208 (43.2%)

125 (41.4%)

71 (48.0%)

8 (44.4%)

0 (0.0%)

4 (66.7%)

HER2

37 (7.7%)

15 (5.0%)

21 (14.2%)

0 (0.0%)

1 (14.3%)

0 (0.0%)

TNBC

60 (12.5%)

37 (12.3%)

20 (13.5%)

2 (11.1%)

0 (0.0%)

1 (16.7%)

LN stage

0

  

78 (52.7%)

14 (77.8%)

7 (100.0%)

1 (16.7%)

1

  

27 (18.2%)

4 (22.2%)

0 (0.0%)

2 (33.3%)

2

  

26 (17.6%)

0 (0.0%)

0 (0.0%)

2 (33.3%)

3

  

17 (11.5%)

0 (0.0%)

0 (0.0%)

1 (16.7%)

Back to article page